medigraphic.com
Instituto Nacional de Salud Pública

2008, Number 5

<< Back Next >>

salud publica mex 2008; 50 (5)

Chronic non-communicable diseases in Mexico: epidemiologic synopsis and integral prevention.

Córdova-Villalobos JA, Barriguete-Meléndez JA, Lara-Esqueda A, Barquera S, Rosas-Peralta M, Hernández-Ávila M, León-May ME, Aguilar-Salinas CA

Language: Spanish
References: 65
Page: 419-427
PDF size: 179.52 Kb.


ABSTRACT

The federal government has implemented several strategies to reduce mortality caused by chronic non-communicable diseases (CNTD). One example is the development of medical units specialized in the care of CNTD (i.e. overweight, obesity, cardiovascular risk and diabetes), named UNEMES (from its Spanish initials). These units –consisting of an ad-hoc, trained, multi-disciplinary team– will provide patient education, help in the resolution of obstacles limiting treatment adherence, and involve the family in patient care. Treatment will be provided using standardized protocols. The efficacy of the intervention will be regularly measured using pre-specified outcomes. We expect that these UNEMES will result in significant savings. In summary, our health care system is developing better treatment strategies for CNTD. Evaluating the performance of the UNEMES will generate valuable information for the design of future preventive actions.


REFERENCES

  1. Rivera JA, Barquera S, Gonzalez-Cossio T, Olaiz G, Sepulveda J. Nutrition transition in Mexico and in other Latin American countries. Nutr Rev 2004;62(7 Pt 2):S149-S157.

  2. González-Pier E, Gutiérrez-Delgado C, Stevens G, Barraza-Lloréns M,Porras-Condey R, Carvalho N, et al. Definición de prioridades para las intervenciones de salud en el Sistema de Protección Social en Salud de México. Salud Publica Mex 2007;49(supl I):S37-S52.

  3. Bodenheimer T, Wagner E, Grumbach K. Improving primary care for patients with chronic illness. JAMA 2002;288:1775-1779.

  4. World Health Organization. Preventing chronic diseases: WHO global report. Genova, Suiza: WHO, 2005.

  5. Aguilar-Salinas CA, Mehta R, Rojas R, Gomez-Perez FJ, Olaiz G, Rull JA.Management of the metabolic syndrome as a strategy for preventing the macrovascular complications of type 2 diabetes: controversial issues. Curr Diab Rev 2005;1:145-158.

  6. Epping-Jordan J, Galea G, Tukuitonga C, Beaglehole R. Preventing chronic diseases: taking stepwise action. Lancet 2005;366:1667-1671.

  7. Lindstr_m J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson J, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-1679.

  8. Satterfiled D, Volansky M, Caspersen C, Engelgau M, Bowman B, Gregg E,et al. Community-based lifestyle interventions to prevent type 2 diabetes. Diab Care 2003;26:2643-2652.

  9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo controlled trial. Lancet 2002;360:7-22.

  10. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.

  11. Aguilar-Salinas CA, Olaiz G, Valles V, Rios JM, Gomez-Perez FJ, et al.High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nation wide survey. J Lip Res 2001;42:1298- 1307.

  12. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Valles V, Rios-Torres JM,Franco A, et al. High prevalence of the metabolic syndrome in Mexico. Arch Med Res 2004;35:76-81.

  13. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Garcia E, Valles V, Ríios-Torres JM, et al. Early onset type 2 diabetes in a Mexican, populationbased,nation-wide survey. Am J Med 2002;113:569-574.

  14. Olaiz G, Rojas R, Barquera S, Shamah T, Aguilar-Salinas C, Cravioto P,et al. Encuesta Nacional de Salud 2000. La salud de los adultos.Cuernavaca, Morelos: Instituto Nacional de Salud Pública, 2003.

  15. Oláiz-Fernández G, Rivera-Dommarco J, Shamah-Levy T, Rojas R,Villalpando-Hernández S, Hernández-Ávila M, et al. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, Morelos: Instituto Nacional de Salud Pública, 2006.

  16. Rojas R, Aguilar-Salinas CA, Gomez-Perez FJ, Valles V, Franco A, Olaiz G, et al. Applicability of the National Cholesterol Education Program III (NCEP-III) Guidelines for treatment of dyslipidemia in a non-Caucasian population: a Mexican Nation-Wide Survey. Rev Inves Clin 2005;57:28-37.

  17. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-2497.

  18. Aguilar-Salinas CA, Velásquez-Monroy O, Gomez-Perez FJ, Gonzalez-Chavez A, Lara-Esqueda A, Molina-Cuevas V, et al. Characteristics of the patients with type 2 diabetes in México: results from a large populationbased, nation-wide survey. Diab Care 2003:26:2021-2026.

  19. International Diabetes Federation. Diabetes Atlas. 2da ed. Bruselas,Bélgica: International Diabetes Federation, 2003.

  20. Rull JA, Aguilar-Salinas CA, Rojas R, Rios-Torres JM, Gomez-Perez FJ, Olaiz G. Epidemiology of type 2 diabetes in Mexico. Arch Med Res 2005;36:188-196.

  21. The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol reduction for type 2 diabetes. JAMA 2002;287:2542-2551.

  22. Saydah S, Fradkin J, Cowie C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-342.

  23. Rosas-Peralta M, Lara-Esqueda A, Pastelin-Hernández G, Velázquez-Monroy O, Martínez-Reding J, Méndez-Ortiz A, et al. Re-encuesta Nacional de Hipertensión Arterial (RENAHTA): Consolidación Mexicana de los factores de riesgo cardiovascular. Cohorte nacional de seguimiento. Arch Cardiol Mex 2005;75:96-111.

  24. Fletcher B, Berra K, Ades P, Braun L, Burke L, et al. Managing abnormal blood lipids. A collaborative approach. Circulation 2005;112:3184-3209.

  25. International Diabetes Federation. Clinical Guidelines Task Force. Guía global para la diabetes tipo 2. Bruselas, Bélgica: International Diabetes Federation, 2006.

  26. Barcelo A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Org 2003;81:19-27.

  27. Strong K, Mathers C, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save. Lancet 2005;366:1578-1582.

  28. Rivera-Gallardo T, Parra-Cabrera S, Barriguete-Meléndez JA. Trastornos de la conducta alimentaria como factor de riesgo para la osteoporosis. Salud Pública Méx 2005;47:308-318.

  29. Barriguete-Meléndez JA, Rivera MT, Pérez A, Emmelhainz M. La conducta alimentaria y el equilibrio bio-psico-familiar. Rev Ibero Psicol 2005;13:68-73.

  30. Salinas JL, Pérez P, Viniegra L, Barriguete-Meléndez JA, Casillas J,Valencia A. Modelo psicodinámico sistémico de evaluación familiar. Rev Inv Clin 1992;44(2):169-188.

  31. Etzwiler DD. Don’t ignore the patients. Diab Care 2001;24:1840-1841.32. Ford ES, Ajani U, Croft J, Crichley J, Labarthe D, et al. Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med 2007;356:2388-2398.

  32. Harris S, Zinman B. Primary prevention of type 2 diabetes in high-risk populations. Diab Care 2000;23:879-881.

  33. Alberti KGMM, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med 2007;24:451-463.

  34. American Diabetes Association. Standards of medical care in diabetes (Position Statement). Diab Care 2004;27(Suppl 1):S15-S36.

  35. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK.Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-2898.

  36. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136.

  37. Aguilar-Salinas CA, Gómez-Pérez FJ. La declaración de Acapulco. Rev Inves Clin 2006;58:71-77.

  38. Doak CM, Visscher TLS, Renders CM, Seidell JC. The prevention of overweight and obesity in children and adolescents: a review of interventions and programmes. Obes Rev 2006;7:111-136.

  39. Finnish Diabetes Association. Implementation of the type 2 diabetes prevention plan in Finland. Finland: Finnish Diabetes Association, 2006.

  40. Australian Centre for Diabetes Strategies. National evidence based guidelines for the management of type 2 diabetes mellitus: primary prevention, case detection and diagnosis. Australia: National Health and Medical Research Council, 2001.

  41. World Health Organization. Non communicable diseases prevention and control. Ginebra, Suiza: World Health Organization, 2006.

  42. Pan American Health Organization. Regional strategy and plan of action on an integrated approach to the prevention and control of chronic diseases, including diet, physical acitivity and health. Washington DC, EU: Pan American Health Organization, 2006

  43. Dowse GK, Gareeboo H, Alberti G, Zimmet P, Tuomilehto-Porran A, Fareed D, et al. Changes in population cholesterol concentrations and other cardiovascular risk factor levels after 5 years of the noncommunicable disease intervention programme in Mauritius. Br Med J 1995;311:1255-1259.

  44. Jacobs-Van der Bruggen M, Bos G, Bemelmans W, Hoogenveen R,Vijgen S, Baan C. Lifestyle interventions are cost-effective in people with different levels of diabetes risk. Diab Care 2007;30:128-134.

  45. Simmons RK, Harding AH, Jakes RW. How much might achievement of diabetes prevention behaviour goals reduce the incidence of diabetes if implemented at the population level? Diabetología 2006;49:905-911.

  46. Mensah G, Goodman R, Zaza S, Moulton A, Kocher P, Dietz W et al.Law as a tool for preventing chronic diseases: expanding the spectrum of effective public health strategies. Preventing Chronic Disease 2004. [Consultado junio 3, 2007]. Disponible en http://www.cdc.gov/ped/ issues/2004/jan/03_0033.htm.

  47. Diabetes Prevention Program Research Group. Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.

  48. Tuomilehto J, Lindstrom J, Eriksson J. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.

  49. Pawal R, Majumdar S, Johnson J, Varney J, McAlister F. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diab Care 2005;28:736-744.

  50. Buchanan T. Can we prevent type 2 diabetes? Diabetes 2007;56:1502-1507.

  51. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Tech Asse 2007;11(17).

  52. Aguilar-Salinas CA, Rull JA, García E, Zúñiga S, Vázquez C, Palacios A, et al. Consenso Mexicano para la Prevención de las Complicaciones Crónicas de la Diabetes tipo 2. Avalado por la Sociedad Mexicana de Nutrición y Endocrinología, Asociación de Medicina Interna de México y la Sociedad de Nutriología. Revi Inves Clin 2000;52:325-363.

  53. Renders CM, Valk G, Griffin S, Wagner E, van Eijk JThM, Assendelft WJJ.Interventions to improve the management of diabetes in primary care, outpatient, and community settings. Diab Care 2001;24:1821-1833.

  54. Shultz EK, Nazareth I, Donegan C, Haines A. Evaluation of general practice computer templates: lessons from a pilot randomized controlled trial. Method Inf Med 1999;38:177-181.

  55. Smith S, Bury G, O’Leary M, Shannon W, Tynan A, Staines A, et al. The North Dublin randomized controlled trial of structured diabetes shared care. Fam Prac 2004;21:39-46.

  56. Landon B, Hicks LRS, O’Malley AJ, Lieu T, Keegan T, Mc Neil BJ, et al. Improving the management of chronic disease at community health centers. N Engl J Med 2007;356:921-934.

  57. Renders CM, Valk GD, Griffin S, Wagner EH, van Eijk JThM, Assendelft WJJ. Interventions to improve the management of diabetes mellitus in primary care, outpatient and community settings. Cochrane Database of Systematic Reviews 2000; Issue 4. Art No. CD001481.

  58. Pérez A, Barriguete-Meléndez JA, Rivera T. Prevención de las alteraciones de la conducta alimentaria en grupos específicos: diabetes mellitus. Rev Iberoam Psicol 2005;13:84-87.

  59. Herman W, Hoerger T, Brandle M, Hicks K, Sorensen S, Zhang P, et al.The cost-effectiveness of lifestyle modification or metformin in preventing Type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323-332.

  60. Eddy D, Schlessinger L, Kahn R. Clinical outcomes and costeffectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251-264.

  61. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Costeffectiveness of the interventions in primary prevention of diabetes among Asian Indians. Diab Care 2007;30:2548-2552.

  62. Gaede P, Vedel P, Larsen N, Jensen G, Parving H, Pedersen O.Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393.

  63. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease with mutiregimen in developing world: a cost-efectiveness analysis. Lancet 2006;368:679-686.

  64. Simmons D, Upjohn M, Gamble GD. Can medication packaging improve glycemic control and blood pressure in type 2 diabetes? Diab Care 2000;23:153-156.

  65. Nathan D, Davidson M, DeFronzo R, Heine R, Henry R, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance. Implications for care. Diab Care 2007;30:753-757.




2020     |     www.medigraphic.com